Proactive Investors - Run By Investors For Investors

Dyadic International taps Ping Rawson as chief financial officer

Rawson previously served as the Dyadic’s chief accounting officer after joining the company in 2016
Handshake
In her new role, Rawson (pictured) will oversee all accounting, financial reporting, treasury and taxes

Dyadic International Inc (NASDAQ:DYAI), a biopharmaceutical Company, is making changes to its executive team by promoting Ping Rawson to chief financial officer.

Rawson previously served as the Dyadic’s chief accounting officer after joining the Company in 2016.

In her new role, Rawson will oversee all accounting, financial reporting, treasury and taxes at the Jupiter, Florida-based Company. She will also work with the executive team to set long-term goals and make operational decisions.

READ: Dyadic International to ring the Nasdaq closing bell to celebrate recent listing, spotlight its tech

The Company’s stock climbed 7.2% to $6.43.

"Since joining Dyadic, Ping has made significant contributions to our Company, initially in her role as Director of Financial Reporting and, more recently, as Chief Accounting Officer. She has taken on increased responsibilities, and demonstrated capabilities in both business and management skills," CEO Mark Emalfarb said. "This past year was a transformational one for Dyadic with our SEC registration and uplisting to Nasdaq. Ping's efforts have been critical to our success."

Dyadic is developing a biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full DYAI profile View Profile

Dyadic International Inc Timeline

Related Articles

patch
May 19 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use